Imaging heart blood flow using a special PET scan
Official title: Myocardial Perfusion Imaging by 15O-H2O PET/CT: Reference Values and Prognostic Value
Run by University of Aarhus · NCT04451551 · Data updated 2026-11-12
This study is testing a special PET scan to see how well it can measure blood flow in the hearts of people with known or suspected heart disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | University of Aarhus Academic / other |
| Locations | 1 site (Aarhus, Aarhus N) |
| Status | Recruiting |
| Started | June 23, 2020 |
| Main results expected | August 1, 2026 |
| Study ends | August 1, 2036 |
| Registry record updated | January 24, 2024 |
| Trial ID | NCT04451551 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with known or suspected ischemic heart disease who are referred for a clinical H2O-PET scan.
✕Probably not a fit
Patients with claustrophobia, severe asthma, or those younger than 18 years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will involve 5000 patients with known or suspected ischemic heart disease who are referred for myocardial perfusion imaging using 15O-H2O PET/CT scans at Aarhus University Hospital. The patients will undergo standard clinical scans at rest and during stress to assess myocardial blood flow. The data collected will help establish reference values for this imaging technique and will be followed up for up to 10 years to evaluate the prognostic significance of the scans in relation to major cardiovascular events.
Why it matters
Potential benefit: If successful, this study could improve the understanding of heart blood flow and its implications for patients with ischemic heart disease.
How similar studies have gone: Other studies using similar imaging techniques have shown promise in assessing myocardial perfusion and predicting cardiovascular events.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Known or suspected ischemic heart disease referred for a clinical H2O-PET at Department of Nuclear Medicine and PET Centre, Aarhus University Hospital Exclusion Criteria: * Claustrophobia, severe asthma, younger than 18 years
Where it's running
-
Aarhus University Hospital
Aarhus, Aarhus N, Denmark Recruiting
Study contacts
- Study coordinator: Simon Madsen, MD
- Email: simmas@rm.dk
- Phone: 4520140596+
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Outpatient Cardiac Telerehabilitation for Ischemic Heart Disease
This study tests whether an outpatient cardiac telerehabilitation program can be as safe and effective as conventional rehab for people with ischemic heart disease.
-
See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease
In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.
-
QFR-guided virtual stenting to optimize PCI before the procedure
We’re testing whether using QFR-based virtual stenting before PCI can improve heart-procedure outcomes compared with standard angiography planning in adults with coronary artery disease.
-
LONG NAGOMI PMCF: follow-up of the Ultimaster Nagomi stent in long coronary artery lesions
This project tests the Ultimaster Nagomi drug-eluting stent in adults undergoing PCI for long coronary lesions to collect real-world safety and effectiveness data.
-
Endocardial delivery of stem-cell derived heart cells to help severe heart failure
This study tests endocardial delivery of HS-001 cell sheets made from iPSC-derived cardiomyocytes in adults with severe heart failure and reduced ejection fraction to see if it is safe and may improve heart function over 26 weeks.
-
Deep learning to analyze and track echocardiograms
This project will test AI tools that help clinicians read echocardiograms and flag adults who may have genetic cardiomyopathy, ischemic heart disease, or cardiac amyloidosis to see if interpretation improves and diagnoses happen faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.